CN120004896A - Flna-结合化合物及其盐酸盐的固体多晶型物 - Google Patents
Flna-结合化合物及其盐酸盐的固体多晶型物 Download PDFInfo
- Publication number
- CN120004896A CN120004896A CN202510171428.0A CN202510171428A CN120004896A CN 120004896 A CN120004896 A CN 120004896A CN 202510171428 A CN202510171428 A CN 202510171428A CN 120004896 A CN120004896 A CN 120004896A
- Authority
- CN
- China
- Prior art keywords
- crystalline
- triazaspiro
- decan
- benzyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808609P | 2019-02-21 | 2019-02-21 | |
| US62/808609 | 2019-02-21 | ||
| PCT/US2020/019305 WO2020172584A1 (en) | 2019-02-21 | 2020-02-21 | Solid polymorphs of a flna-binding compound and its hydrochloride salts |
| CN202080030057.XA CN114072406B (zh) | 2019-02-21 | 2020-02-21 | Flna-结合化合物及其盐酸盐的固体多晶型物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080030057.XA Division CN114072406B (zh) | 2019-02-21 | 2020-02-21 | Flna-结合化合物及其盐酸盐的固体多晶型物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120004896A true CN120004896A (zh) | 2025-05-16 |
Family
ID=72141575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510171428.0A Pending CN120004896A (zh) | 2019-02-21 | 2020-02-21 | Flna-结合化合物及其盐酸盐的固体多晶型物 |
| CN202080030057.XA Active CN114072406B (zh) | 2019-02-21 | 2020-02-21 | Flna-结合化合物及其盐酸盐的固体多晶型物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080030057.XA Active CN114072406B (zh) | 2019-02-21 | 2020-02-21 | Flna-结合化合物及其盐酸盐的固体多晶型物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11370791B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3927707A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7895041B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210135530A (cg-RX-API-DMAC7.html) |
| CN (2) | CN120004896A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020224678B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021016622A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3131146A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285763A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020172584A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882428B1 (en) | 2012-07-13 | 2019-01-16 | Pain Therapeutics, Inc. | A method of inhibiting tau phosphorylation |
| JP7895041B2 (ja) | 2019-02-21 | 2026-07-27 | フィラナ セラピューティクス インコーポレイテッド | Flna結合化合物及びその塩酸塩の固体多形 |
| WO2022098700A1 (en) * | 2020-11-03 | 2022-05-12 | Cassava Sciences, Inc. | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004014304A1 (de) * | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen |
| US8614324B2 (en) * | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US8653068B2 (en) * | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US9340558B2 (en) * | 2007-11-02 | 2016-05-17 | Pain Therapeutics Inc. | Filamin a binding anti-inflammatory and analgesic |
| EP2488177B1 (en) * | 2008-10-31 | 2016-10-12 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| WO2011119559A1 (en) * | 2010-03-25 | 2011-09-29 | Schering Corporation | Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
| EP2882428B1 (en) * | 2012-07-13 | 2019-01-16 | Pain Therapeutics, Inc. | A method of inhibiting tau phosphorylation |
| EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| US9433604B2 (en) | 2013-10-08 | 2016-09-06 | Pain Therapeutics Inc. | Method for inhibiting growth of cancer cells |
| JP7895041B2 (ja) | 2019-02-21 | 2026-07-27 | フィラナ セラピューティクス インコーポレイテッド | Flna結合化合物及びその塩酸塩の固体多形 |
-
2020
- 2020-02-21 JP JP2021549470A patent/JP7895041B2/ja active Active
- 2020-02-21 AU AU2020224678A patent/AU2020224678B2/en active Active
- 2020-02-21 EP EP20759180.1A patent/EP3927707A4/en active Pending
- 2020-02-21 CA CA3131146A patent/CA3131146A1/en active Pending
- 2020-02-21 CN CN202510171428.0A patent/CN120004896A/zh active Pending
- 2020-02-21 WO PCT/US2020/019305 patent/WO2020172584A1/en not_active Ceased
- 2020-02-21 CN CN202080030057.XA patent/CN114072406B/zh active Active
- 2020-02-21 BR BR112021016622A patent/BR112021016622A2/pt unknown
- 2020-02-21 US US16/798,041 patent/US11370791B2/en active Active
- 2020-02-21 KR KR1020217030333A patent/KR20210135530A/ko not_active Ceased
-
2021
- 2021-08-22 IL IL285763A patent/IL285763A/en unknown
-
2022
- 2022-06-27 US US17/850,198 patent/US12065440B2/en active Active
-
2024
- 2024-01-18 JP JP2024005868A patent/JP2024054139A/ja active Pending
- 2024-08-13 US US18/802,950 patent/US20240400566A1/en active Pending
- 2024-11-21 US US18/955,947 patent/US12391693B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20250084083A1 (en) | 2025-03-13 |
| CN114072406B (zh) | 2025-03-18 |
| BR112021016622A2 (pt) | 2021-11-03 |
| US20220340574A1 (en) | 2022-10-27 |
| US12391693B2 (en) | 2025-08-19 |
| JP2022523196A (ja) | 2022-04-21 |
| EP3927707A1 (en) | 2021-12-29 |
| IL285763A (en) | 2021-10-31 |
| CN114072406A (zh) | 2022-02-18 |
| US20200270250A1 (en) | 2020-08-27 |
| US11370791B2 (en) | 2022-06-28 |
| WO2020172584A1 (en) | 2020-08-27 |
| KR20210135530A (ko) | 2021-11-15 |
| AU2020224678B2 (en) | 2024-03-14 |
| US12065440B2 (en) | 2024-08-20 |
| CA3131146A1 (en) | 2020-08-27 |
| EP3927707A4 (en) | 2022-11-09 |
| JP7895041B2 (ja) | 2026-07-27 |
| NZ779310A (en) | 2024-01-26 |
| US20240400566A1 (en) | 2024-12-05 |
| JP2024054139A (ja) | 2024-04-16 |
| AU2020224678A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9193730B2 (en) | Short-acting benzodiazepine salts and their polymorphic forms | |
| US12391693B2 (en) | Solid polymorphs of a FLNA-binding compound and its hydrochloride salts | |
| JP6447508B2 (ja) | 3−(イミダゾ[1,2−b]ピリダジン−3−イルエチニル)−4−メチル−N−{4−[(4−メチルピペラジン−1−イル)メチル]−3−(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形 | |
| CN121758378A (zh) | Btk抑制剂的晶型 | |
| KR20230038229A (ko) | 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도 | |
| US12209073B2 (en) | Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor | |
| TW201718516A (zh) | 組蛋白去乙醯酶抑制劑之晶形 | |
| US20150322084A1 (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | |
| US8987243B2 (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt | |
| Reutzel-Edens | Analytical Techniques and Strategies for Salt/Co-crystal | |
| US20150299162A1 (en) | Solid forms of | |
| US20260070928A1 (en) | Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof | |
| US12624027B2 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine | |
| KR20260066052A (ko) | 베주클라스티닙의 결정형, 이의 제조방법 및 이의 용도 | |
| WO2026072992A1 (en) | Salts and solid forms of muscarinic receptor agonists | |
| WO2024255833A1 (zh) | 吡啶氮氧化合物与富马酸的共晶体及其组合物、用途和制备方法 | |
| JP2020535210A (ja) | ジアザビシクロオクタン誘導体の剤形およびその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |